Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Alexza Pharmaceuticals, Inc. |
---|---|
Information provided by: | Alexza Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT00603980 |
Compare the abuse liabilities of Staccato Alprazolam, oral immediate-release alprazolam, and Staccato Placebo.
Condition | Intervention | Phase |
---|---|---|
Abuse Liability of Staccato Alprazolam |
Drug: alprazolam Drug: placebo |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Crossover Assignment, Pharmacodynamics Study |
Official Title: | Abuse Liability Study of Staccato® Alprazolam for Inhalation in Subjects With Histories of Sedative Abuse |
Estimated Enrollment: | 14 |
Study Start Date: | January 2008 |
Estimated Study Completion Date: | February 2009 |
Estimated Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Low dose
|
Drug: alprazolam
Staccato Alprazolam, single dose
|
2: Experimental
Middle dose
|
Drug: alprazolam
Staccato Alprazolam, single dose
|
3: Experimental
High dose
|
Drug: alprazolam
Staccato Alprazolam, single dose
|
4: Active Comparator
Low dose
|
Drug: alprazolam
oral, immediate release
|
5: Active Comparator
Middle dose
|
Drug: alprazolam
oral, immediate release
|
6: Active Comparator
High dose
|
Drug: alprazolam
oral, immediate release
|
7: Placebo Comparator
Double placebo
|
Drug: placebo
Staccato placebo + oral placebo
|
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Daniel A Spyker, MD | 650-944-7272 | dspyker@alexza.com |
United States, Maryland | |
Johns Hopkins University School of Medicine | Recruiting |
Baltimore, Maryland, United States, 21224 | |
Contact: Roland R Griffiths, PhD 410-550-0034 rgriff@jhmi.edu | |
Principal Investigator: Roland R Griffiths, PhD |
Principal Investigator: | Roland R Griffiths, PhD | Johns Hopkins University |
Responsible Party: | Alexza Pharmaceuticals, Inc ( Daniel A. Spyker, MD / Sr Director, Drug Safety & Pharmacovigilance ) |
Study ID Numbers: | AMDC-002-102, November 14, 2007 |
Study First Received: | January 17, 2008 |
Last Updated: | January 8, 2009 |
ClinicalTrials.gov Identifier: | NCT00603980 |
Health Authority: | United States: Food and Drug Administration |
Alprazolam |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action GABA Modulators Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants |
Pharmacologic Actions Therapeutic Uses Hypnotics and Sedatives GABA Agents Anti-Anxiety Agents Central Nervous System Agents |